The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.
Ruan DY, Wei XL, Liu FR, Hu XC, Zhang J, Ji DM, Huang DZ, Zhao YQ, Pan HM, Liao WJ, Yang KY, Xu N, Lu XX, Chen YL, Zhang W, Zhou H, Zhao HY, Xu RH.
Ruan DY, et al. Among authors: zhao yq.
J Hematol Oncol. 2024 Nov 29;17(1):118. doi: 10.1186/s13045-024-01644-4.
J Hematol Oncol. 2024.
PMID: 39614368
Clinical Trial.